Related Experiment Video

Updated: Oct 6, 2025

Histological Quantification of Chronic Myocardial Infarct in Rats
09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

14.8K

Association between C-Reactive Protein Velocity and Left Ventricular Function in Patients with ST-Elevated Myocardial

Ariel Banai1, Dana Levit1, Samuel Morgan1

  • 1Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 64239, Israel.

Journal of Clinical Medicine
|January 21, 2022
PubMed

Insights

C-reactive protein velocity (CRPv) predicts left ventricular systolic and diastolic dysfunction in ST-elevation myocardial infarction (STEMI) patients after primary PCI. This inflammatory marker offers valuable prognostic insights.

Area of Science:

  • Cardiology
  • Biomarkers
  • Echocardiography

Background:

  • C-reactive protein velocity (CRPv) is an inflammatory biomarker linked to adverse outcomes in ST-elevation myocardial infarction (STEMI) patients post-primary percutaneous intervention (PCI).
  • Limited data exists on CRPv's association with left ventricular (LV) systolic and diastolic function assessed by echocardiography.

Purpose of the Study:

  • To investigate the relationship between CRPv and echocardiographic parameters of LV systolic and diastolic function in STEMI patients undergoing primary PCI.
  • To determine if CRPv can predict severe systolic and diastolic dysfunction.

Main Methods:

  • Analysis of echocardiographic data and CRPv in 1059 STEMI patients treated with primary PCI.
  • Stratification of patients into tertiles based on CRPv values.
  • Utilizing receiver operating characteristic (ROC) curve analysis to identify optimal CRPv cut-off values for predicting severe LV dysfunction.

Main Results:

  • Higher CRPv tertiles were associated with significantly lower left ventricular ejection fraction (LVEF).
  • CRPv independently predicted LVEF ≤ 35% and grade III diastolic dysfunction.
  • CRPv demonstrated a superior diagnostic performance for severe systolic dysfunction compared to C-reactive protein (CRP) alone.

Conclusions:

  • CRPv serves as a valuable marker for both systolic and diastolic dysfunction in STEMI patients treated with primary PCI.
  • Further extensive research is warranted to corroborate these findings and explore clinical implications.

Keywords:
CRP velocitySTEMIdiastolic dysfunctionsystolic dysfunction

More Related Videos

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.0K
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

11.7K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
250
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
38
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
102
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
388
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
70
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
29